---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216777"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-05-11T20:10:44+00:00"
generated_at: "2026-05-11T22:18:44.894263+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports Q1 2026 net loss of $26.2M; cash raised to $271M

## Summary
- Net loss $26.2M ($0.25/share) vs. $18.2M net loss in Q1 2025; R&D spend up 50% YoY to $21.4M.
- Cash, equivalents & short-term investments $271M as of Mar 31, 2026, up from $145M at Dec 31, 2025; includes $164M net from Feb 2026 offering.
- Cash runway expected into late 2027 to support clinical milestones; lead program VMT-α-NET advancing to Cohort 4 and meningioma cohort.
- VMT01 (melanoma) dosing cohorts closed after 10 patients treated at 3.0 mCi; PSV359 (FAP) Cohort 3 open.
- Chicago manufacturing site on track to complete construction in 2026.

## SEC filing metadata
- accession: 0001193125-26-216777
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-05-11T20:10:44+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/0001193125-26-216777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/catx-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216777
- JSON: https://secwatch.observer/filing/0001193125-26-216777.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216777.txt

## Key facts
- Earnings Releases
  Perspective Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: On May 11, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/0001193125-26-216777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.